Ethidium bromide Clinical Trials

Size	Price	Qty
25mg	USD 147

Clinical Trials

Multiple clinical trials are evaluating therapeutic strategies for B-cell non-Hodgkin's lymphoma, epidermolysis bullosa, severe aplastic anemia, vision disorders, and acute cerebral ischemia. Spanning Phase 1/2 safety evaluations to Phase 2/3 efficacy trials, Phase 4 post-market assessments, and behavioral interventions, these studies encompass both active and not-yet-recruiting statuses. This research landscape is sponsored by corporate entities, including Estrella Biopharma, TWi Biotechnology, and Pharmazz, as well as academic institutions like Radboud University and the 920th Hospital.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06343311	Not yet recruiting	B-Cell Non-Hodgkin''s Lymphoma (NHL)\|Lymphoma Non-Hodgkins\|Lymphomas Non-Hodgkin''s B-Cell\|Non-Hodgkin Lymphoma\|Non-Hodgkin''s Lymphoma\|Large B-Cell Lymphoma\|Lymphoma Non-Hodgkin''s Adult\|Lymphoma\|Refractory Non-Hodgkin Lymphoma\|Relapsed Non-Hodgkin Lymphoma\|Lymphoma Non-Hodgkin\|HIV Associated Lymphoma\|CNS Lymphoma\|High-grade B-cell Lymphoma\|Refractory B-Cell Non-Hodgkin Lymphoma	Estrella Biopharma Inc.\|Eureka Therapeutics Inc.\|Estrella Immunopharma Inc.	2024-05-15	Phase 1\|Phase 2
NCT06073132	Recruiting	Generalized Epidermolysis Bullosa Simplex	TWi Biotechnology Inc.	2024-04	Phase 2\|Phase 3
NCT06378060	Recruiting	Severe Aplastic Anemia	Hematology department of the 920th hospital	2024-03-01	Phase 2
NCT05600140	Recruiting	Vision Disorders\|Vision Low	Royal Dutch Visio\|Radboud University Behavioural Science Institute Nijmegen The Netherlands	2024-03-06	Not Applicable
NCT06007235	Recruiting	Epidermolysis Bullosa Dystrophica\|Epidermolysis Bullosa Junctional	Organ Tissue Regeneration Repair and Replacement\|Euraxi Pharma\|ARANZ Medical	2024-01-29	Not Applicable
NCT05955326	Recruiting	Acute Cerebral Ischemia	Pharmazz Inc.	2024-01-08	Phase 4

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Ethidium bromide product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Ethidium bromide functions as a planar intercalating agent that inserts between adjacent DNA base pairs, deforming the helical structure and blocking downstream nucleic acid transcription and replication machinery. This persistent inhibition of DNA synthesis arrests cell cycle progression and induces cytotoxic cell death, highlighting its clinical relevance in suppressing abnormal cellular proliferation in malignancies such as B-cell non-Hodgkin's lymphoma.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).